Treatment in patients with recurrent infections and IgG Subclass Deficiency, and/or Deficient Anti-Polysaccharide Antibody Response. - Treatment of IgG Subclass Deficiency and/or Deficiency of Anti-Polysaccharide Antibody Response

Sanquin Plasma Products0 个研究点开始时间: 2007年8月9日最近更新: 2012年3月19日

适应症

试验速览

暂无简介。

•Adults (= 18 years of age), IUWP2005.01A, Children (= 5-18 years of age), IUWP2005.01B
•IgG subclass deficiency, and/or (selective) antipolysaccharide antibody deficiency, and at least 2 physician documented infections before the start of the current treatment or in the last 6 months for newly diagnosed patients.
•Are the trial subjects under 18? yes
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•Treatment with any other investigational drug within 7 days prior to study entry, or previous enrolment in this study
•Known with allergic reactions against human plasma or plasma products, or allergy against co-trimoxazol
•an ongoing progressive terminal disease, including HIV infection
•Pregnancy or lactation
•Previous history of (transient) cerebrovascular accident or coronary insufficiency.
•renal insufficiency (plasma creatinin > 115 µmol/L; or creatinin clearance <20 ml/min))
•an ongoing active disease causing general symptoms e.g. chronic active hepatitis or persistent enterovirus infection with ongoing systemic complains.
•detectable anti-IgA antibodies
•active SLE
•Known with glucose-6-phosphate hydrogenase deficiency

发起方

Sanquin Plasma Products